Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints

Patrick Rossignol^{1,2*}, Rajiv Agarwal^{3,4}, Bernard Canaud⁵, Alan Charney⁶, Gilles Chatellier⁷, Jonathan C. Craig^{8,9}, William C. Cushman¹⁰, Ronald T. Gansevoort¹¹, Bengt Fellström¹², Dahlia Garza¹³, Nicolas Guzman¹⁴, Frank A. Holtkamp^{15,16}, Gerard M. London^{2,17}, Ziad A. Massy^{2,18}, Alexandre Mebazaa^{2,19,20,21}, Peter G. M. Mol^{15,16}, Marc A. Pfeffer²², Yves Rosenberg²³, Luis M. Ruilope²⁴, Jonathan Seltzer²⁵, Amil M. Shah²², Salim Shah²⁶, Bhupinder Singh²⁷, Bergur V. Stefánsson²⁸, Norman Stockbridge²⁹, Wendy Gattis Stough³⁰, Kristian Thygesen³¹, Michael Walsh³², Christoph Wanner³³, David G. Warnock³⁴, Christopher S. Wilcox³⁵, Janet Wittes³⁶, Bertram Pitt³⁷, Aliza Thompson²⁹, and Faiez Zannad^{1,2}

¹Inserm, Centre d'Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; Université de Lorraine; Association Lorraine pour le Traitement de l'Insuffisance Rénale, Institut lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 rue du Morvan, 54500, Nancy, France; ²F-CRIN INI-CRCT, Nancy, France; ³Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; ⁴Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA; ⁵Fresenius Medical Care Deutschland and University of Montpellier, UFR Medicine, France; ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ⁷AP-HP, Hôpital Européen Georges Pompidou, Unité de Recherche Clinique and INSERM CIC 1418, Paris, France; ⁸School of Public Health, The University of Sydney, New South Wales, Australia; ⁹Centre for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia; ¹⁰Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee, USA; ¹¹Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ¹²Inserm U1018, Université Paris-Saclay, UVSQ, Université Paris-Sud, Villejuif, France; ¹³Relypsa, Inc., Redwood City, CA, USA; ¹⁴AstraZeneca, Gaithersburg, MD, USA; ¹⁵Dutch Medicines Evaluation Board, Utrecht, The Netherlands; ¹⁶Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ¹⁷France Centre Hospitalier F.H. Manhès, Fleury-Merogis, France; ¹⁸Ambroise Pare University Hospital, APHP, Paris-Ile-de France-Ouest University (UVSQ), and INSERM U1018, Team 5 Boulogne Billancourt, France; ¹⁹U942 Inserm, Paris, France; ²⁰University Paris Diderot, Sorbonne Paris Cité, Paris, France; ²¹APHP, Department of Anesthesia and Critical Care, Hôpitaux Universitaires Saint Louis-Lariboisière, Paris, France; ²²Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; ²³National Heart, Lung, and Blood Institute, Bethesda, MD, USA; ²⁴Institute of Investigation and Hypertension Unit, Hospital 12 de Octubre, Department of Preventive Medicine and Public Health, Universidad Autonoma and School of Doctoral Studies and Research, Universidad Europea de Madrid, Madrid, Spain; ²⁵ACI Clinical, Bala Cynwyd, PA, USA; ²⁶Sarfez Pharmaceuticals, Inc., McLean, VA, USA; ²⁷ZS Pharma, San Mateo, CA, USA; ²⁸AstraZeneca, Gothenburg, Sweden; ²⁹Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; ³⁰Campbell University College of Pharmacy and Health Sciences, NC, USA; ³¹Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; ³²McMaster University and Population Health Research Institute, Hamilton, Canada; ³³Division of Nephrology, Department of Internal Medicine 1, University Hospital Würzburg and Comprehensive Heart Failure Center, Würzburg, Germany; ³⁴Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; ³⁵Hypertension, Kidney and Vascular Research Center and Division of Nephrology and Hypertension, Department of Medicine, Georgetown University, Washington, DC, USA; ³⁶Statistics Collaborative, Inc., Washington, District of Columbia, USA; and ³⁷University of Michigan School of Medicine, Ann Arbor, MI, USA

Received 10 February 2017; revised 17 March 2017; editorial decision 29 March 2017; accepted 30 March 2017; online publish-ahead-of-print 18 April 2017

Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and

* Corresponding author. Tel: +33 3 83 15 73 20, Fax: +33 3 83 15 73 24, Email: p.rossignol@chru-nancy.fr

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.

Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.

Keywords

Cardiovascular diseases • Chronic renal insufficiency • Chronic kidney failure • Clinical trials as topic

Introduction

Cardiovascular disease is a major health burden for patients with chronic kidney disease (CKD), and therapies are needed to improve cardiovascular outcomes in this population.¹ Although some cardiovascular trials have been designed to recruit appropriately sized subgroups of patients with CKD,² most cardiovascular clinical trials exclude patients with advanced CKD or underreport characteristics relevant to CKD [e.g. baseline serum creatinine, creatinine clearance, estimated glomerular filtration rate (eGFR), the extent of albuminuria].^{3,4} Consequently, the efficacy and safety of cardiovascular therapies in these patients is uncertain.^{5–7}

Cardiovascular outcome trials are challenging to conduct in CKD populations, but well-designed randomized controlled trials are needed to inform optimal management of these patients.^{8,9} Promoting meaningful progress in this area requires identifying and addressing the specific impediments to conducting cardiovascular outcome trials in patients with CKD.

The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) is an international organization of academic cardiovascular and renal clinical trialists dedicated to improving outcomes among patients who have both chronic kidney and cardiovascular disease. To advance cardiovascular outcomes research in patients with CKD, INI-CRCT convened a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology, within the framework of a Cardiovascular Clinical Trialists (CVCT) workshop to discuss challenges associated with designing cardiovascular outcome trials in CKD. This paper summarizes the insights from the INI-CRCT meeting and identifies a research agenda to advance the field.

Patient selection

Few large cardiovascular outcome trials have been conducted specifically in the CKD or end-stage kidney disease (ESKD) populations on dialysis¹⁰ (Supplementary material online, Table S1). Some trials have reported beneficial treatment effects on cardiovascular outcomes,^{11,12} but others were inconclusive because of study design limitations (e.g. open-label, small sample size, suboptimal target population).

The pathophysiologic mechanisms of CKD that predispose patients to cardiovascular disease and subsequent cardiovascular events are complex and overlapping (Figure 1).^{1,5} As CKD progresses, more pathophysiologic pathways are potentially involved in

downstream cardiovascular events. Whether a single pathophysiologic pathway predominates, or if the processes collectively contribute to cardiovascular events, is unclear. If the latter, a single therapy is unlikely to have a sizable benefit. Additionally, as CKD progresses to irreversible ESKD, the potential for any treatment to exert a beneficial effect on morbidity and mortality may diminish.

Some authors have argued that targeting early CKD stages is important for cardiovascular primary prevention trials.⁵ Although this population has lower event rates than does an advanced ESKD population, the increased sample size consequent on this lower event rate may be offset by the greater likelihood of modifiable risk in earlier CKD stages and the potential for a larger treatment effect. In contrast, although ESKD patients are more likely to have high event rates, non-cardiovascular causes may account for a substantial portion of events, and these events may be less likely to respond to a cardiovascular therapy.¹⁰ Enrolling patients at high risk for cardiovascular events (i.e. late or end-stage CKD) in clinical trials can reduce the sample size, but only if the patients are at risk of an outcome that the treatment can influence. Otherwise, many of the events constitute ‘noise’, thus reducing the power of a trial.^{13,14} Critical steps to advance the field include conducting studies to better characterize the CKD pathophysiology that contributes to cardiovascular outcomes, developing therapies that interrupt these pathophysiologic processes, identifying patients with the target pathophysiology, and enrolling these patients in randomized controlled trials to test the intervention (Figure 2). Cardiovascular clinical trials should report the distribution of patients across CKD stages, and where feasible, examine trial results according to pre-specified CKD stage subgroups. Such analyses, while not definitive, can provide insight into the consistency of treatment effects across subgroups of CKD severity and inform the design of future studies.

An important aspect of designing a clinical trial is identifying a patient population with the disease of interest in whom the outcome of interest is likely to occur over the course of the trial. Imaging and biomarkers are widely used in cardiovascular clinical trials to establish the presence of relevant phenotypic disease characteristics and for enrichment, but criteria and cut-points used to establish the presence of diseases such as heart failure in patients with advanced CKD or those on dialysis may need to be modified.¹⁵ For example, the Acute Dialysis Quality Initiative (ADQI) has proposed that at least 1 of 8 echocardiographic criteria¹⁶ should be abnormal (based on the thresholds of the American Association of Echocardiography consensus guideline¹⁷) to establish echocardiographic evidence of structural heart disease in patients with ESKD on dialysis.

Biomarkers (e.g. cardiac troponin [cTn], B-type natriuretic peptide, urinary albumin or urinary protein excretion rate, calcification propensity assay) may also guide optimal patient selection if used to select for a population with a form of disease that is likely to be affected by the intervention. For example, cTn levels above a reference value are prognostic for all-cause mortality in stable haemodialysis patients.¹⁸ Although a cTn concentration above some value may select a study population that is at greater risk of death, this approach would be helpful only if the probability is reasonably high that the treatment under study would impact the specific type of mortality predicted by elevations in cTn concentrations.

Endpoint selection and definitions in chronic kidney disease cardiovascular outcome trials

Endpoint definitions

A task force has developed a standard set of definitions for cardiovascular endpoint events for cardiovascular clinical trials.¹⁹ Although this effort represents an important advance for cardiovascular outcome trials, outstanding questions remain regarding whether these definitions are optimal for trials conducted in patients with advanced CKD, including those on dialysis (Table 1).²⁰ For example, the standard definition of a heart failure endpoint event requires the presence of at least one new or worsening symptom, objective evidence of heart failure, and initiation or intensification of treatment for heart failure.¹⁹ However, many physical manifestations of CKD overlap with those of heart failure. Indeed, signs of volume overload and symptoms of

Table 1 Limitations of standard endpoint definitions in patients with chronic kidney disease

- Difficult to determine whether some signs and symptoms commonly used to identify an endpoint event (e.g. heart failure) are attributable to cardiovascular disease or to the underlying kidney disease
- Heterogeneity in clinical practice (e.g. decision to hospitalize, decision to dialyze)
- Some biomarkers (e.g. natriuretic peptides) may be altered in chronic kidney disease and interpretation can be challenging, whereas kidney specific criteria do not appear to be needed for other biomarkers (e.g. cardiac troponin to diagnose acute myocardial infarction)

dyspnea in patients on dialysis could be due to a missed haemodialysis session, overestimation of dry weight, or non-adherence to dietary sodium and fluid restrictions. Biomarker findings, such as elevated natriuretic peptide levels, which can provide laboratory evidence of new or worsening heart failure, may result from decreased renal clearance of these markers in patients with CKD. Imaging findings may also be difficult to interpret. For example, in patients with ESKD, right heart pressures increase before haemodialysis.^{16,21,22} For these reasons, it may be difficult to determine whether symptoms and signs suggestive of heart failure result from impaired kidney function, true heart failure, or both. Moreover, clinical patient management (i.e. the decision to hospitalize for heart failure symptoms or not, what constitutes an urgent heart failure visit in the dialysis setting) is substantially heterogeneous across and within countries, which makes application of standard definitions of heart failure events difficult, even in studies that use endpoint adjudication committees. Although this problem is not unique to clinical trials in patients with kidney disease, it may be exacerbated in this population. All these factors may lead to inaccurate identification of heart failure events and create challenges for conducting and interpreting study results. Clinical trials of haemodialysis patients could use the staging system the AQDI proposed (Figure 3) to define heart failure endpoint events if the prognostic value of the system is validated in robust, prospective trials.¹⁶

Diagnosing acute MI in patients with CKD and elevated cTn levels presents a clinical dilemma and often requires extended evaluation for an accurate diagnosis. However, studies suggest that cTn level is equally effective in diagnosing MI in patients with CKD and those with normal renal function.²³ If the level of elevated cTn values is unchanging, and the timing of the event makes a rising and/or falling pattern unlikely, the elevated cTn level, even if substantial, likely reflects chronic myocardial injury. However, if a rising and/or falling pattern of the cTn values is present then the aetiology of the abnormal cTn values could be, for example, acute heart failure or acute MI. A diagnosis of acute MI is more likely when a rising and falling pattern is accompanied by ischaemic symptoms, new ischaemic electrocardiogram changes, or loss of myocardial function by imaging. No data suggest CKD patients require different criteria for the cTn decision levels.²⁴

Composite endpoints

Many cardiovascular outcome trials use composite endpoints to increase the event rate, and therefore increase the power (if the treatment exerts an effect on all components of the composite), or to reduce the sample size or decrease the duration of a clinical trial.²⁵

Composite endpoints may also be chosen to characterize the clinical picture more comprehensively, since outcomes other than mortality are important to patients.^{25–27} As others have noted, the limitations of composite endpoints can overshadow their strengths if the individual components differ greatly in their importance or diverge in their response to treatment, thus clouding interpretation and reducing statistical power.^{14,27}

The most suitable choice of components of the composite endpoint for a cardiovascular outcome trial conducted specifically in the CKD population depends on the specific therapy being tested. In general, a cause-specific (i.e. cardiovascular) composite primary efficacy endpoint, in contrast to one that includes all-cause mortality, may be more appropriate for cardiovascular outcome trials in CKD patients since non-cardiovascular causes of death are not uncommon in the CKD population and the intervention is unlikely to reduce the rate of such deaths. A treatment's effect on all-cause mortality would still need to be examined from a safety perspective. Renal endpoints are relevant in a CKD population even if the primary intervention target is cardiovascular disease, and a composite endpoint reflecting both cardiovascular and renal outcomes may be desirable, especially if the intervention is expected to affect both systems. A challenging problem is which endpoints to combine and how to interpret the results of the composite endpoint. The Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE) (NCT02065791) trial is an ongoing study designed to enroll 4200 patients with CKD and compare the effect of canagliflozin to placebo on the primary endpoint of time-to-first end-stage kidney disease, doubling of serum creatinine, renal death, or cardiovascular death.²⁸ Inspection of the treatment effect on each component individually will be critical to the interpretation of this study to assess whether a single component drove the overall effect, or whether all components showed consistent effects.

The typical approach to analysis of composite outcomes in clinical trials has been to compare treatment groups with respect to the time to the first event in the composite. A variety of statistical methods are available that consider not only the first event but also events that occur after the first event.²⁹ Novel methods that analyse components in order of clinical severity or that account for differential effect among the components of the composite have generated interest among clinical trialists.^{25,30} Application of these methods may be particularly beneficial for cardiovascular outcomes trials in CKD, since composite endpoints are likely to be constructed with components of differing clinical significance (i.e. for CKD early stages: cardiovascular death combined with a change in renal function; for advanced

Figure 3 Acute dialysis quality initiative heart failure in end stage kidney disease classification system. Classification is determined by an assessment of dyspnea before and after renal replacement therapy (RRT)/ultrafiltration (UF). Patients who have the same class assessment before and after RRT/UF are scored by their post-treatment assessment. The classification scheme assumes that the class assignment represents the patient's achievement of optimized UF and is representative of the patient's usual level of dyspnea before and after RRT/UF. *If dyspnea symptoms improve to class I levels, the patient would be classified as class 2R. †If dyspnea symptoms improve to class II levels, the patient would be classified as class 3R. ADQI, Acute Dialysis Quality Initiative; ESKD, end-stage renal disease; NYHA, New York Heart Association. Reprinted with permission from Chawla et al. *J Am Coll Cardiol* 2014;63:1246–1252.

CKD: CV death, chronic renal replacement therapy or a GFR <15 mL/min/1.73 m² or a change in renal function). When a treatment is anticipated to have different effects on the various outcomes within the composite the analysis must recognize the correlation of the multiple events within a person and must be designed in a way that captures these effects.

Competing risks

Most cardiovascular outcome trials use composite primary endpoints to evaluate both survival and clinically relevant endpoints that measure the patients' morbidity. Competing risks can be challenging when using composite endpoints. Patients with CKD, and especially ESKD on dialysis, are at high risk of non-cardiovascular causes of death (e.g. sepsis, malignancy). Obviously, patients who die from non-cardiovascular causes are no longer at risk for cardiovascular death. The extent to which competing risks might bias the study result depends on the number, type, and distribution of deaths in a study. The complications of competing risks can be avoided if all-cause mortality is the endpoint, but, as previously noted, this approach may not be prudent or even feasible because of the necessary sample size. More research is needed to determine the clinical importance and relevance of competing risks analysis in cardiovascular outcomes trials studying patients with CKD and to ensure

statistical analysis plans account for competing risks where appropriate to ensure unbiased presentation of results.

Cardiovascular clinical trialists recognize the importance of patient-reported outcomes, particularly in disease states with high morbidity (e.g. heart failure).²⁶ While it would be hard to demonstrate an acceptable benefit:risk ratio for a small treatment effect on symptoms in a population where the background rate of important events (e.g. death) is high, understanding whether a treatment affects the key symptoms of a disease is important. From a regulatory perspective, a meaningful effect on patient symptoms could result in additional labelling claims. Patient-reported endpoints are also necessary for health technology assessments and can provide clinicians and patients with useful information to support patient education and decision-making.³¹

Research agenda to advance clinical trial science and improve patient outcomes in chronic kidney disease

The INI-CRCT recommends the following research priorities to advance the field towards achieving improved cardiovascular outcomes for patients with CKD:

- (1) Conduct analyses to evaluate composite endpoints, testing various combinations of endpoints that reflect cardiovascular and renal outcomes across the spectrum of CKD, including ESKD on dialysis. Registry cohorts, electronic medical records, and databases from completed clinical trials may be appropriate data sources for such studies.
- (2) Conduct analyses to (i) determine the impact of competing risks in analysis of cardiovascular outcome trials of patients across the CKD spectrum using various composite endpoints constructed with both cardiovascular and renal components; and (ii) provide guidance for selecting appropriate analytic methods to handle competing risks for specific CKD/ESKD populations based on the components of the endpoints.
- (3) Develop patient-reported outcomes as supportive endpoints (i.e. secondary endpoints or endpoints to support health technology assessment), raise awareness about sources of bias when using these endpoints, and provide guidance to researchers about methods to minimize bias (e.g. avoiding missing data, using statistically valid methods for handling missing data).
- (4) Develop a core set of cardiovascular outcomes that are critical to decision making by patients/caregivers, clinicians and regulators, and that are defined and reported in a standard way that allows robust conclusions of relative effectiveness.
- (5) Harmonize evaluation metrics and clinical data definitions (e.g. for an heart failure event) for cardiovascular trials in patients on dialysis to facilitate research and improve management of dialysis patients.³²

Conclusions

Because of the linkage of cardiovascular and renal disease and prevalence of cardiovascular disease in patients with CKD, therapies are needed to improve cardiovascular outcomes in patients with CKD. This common objective among cardiovascular and renal clinical trialists creates an opportunity to collaborate in the design of rigorous clinical trials that address the specific needs of the CKD population. The INI-CRCT has identified priority areas for research, primarily involving selection of patients and endpoints, and aims to pursue collaborative initiatives among cardiovascular and renal clinical trialists to encourage relevant research efforts. This research should inform the design of future clinical trials and ultimately generate robust evidence to guide the management of CKD patients with cardiovascular disease (Figure 4).

Supplementary material

Supplementary material is available at *European Heart Journal* online.

Acknowledgements

This work was generated from discussions during a workshop held in Washington, DC in June 2016. It was organized jointly by the INI-CRCT, Nancy, France, and CVCT (Cardiovascular Clinical Trialists), under the framework of the Clinical Investigation Center (CIC)

Figure 4 Research agenda. Completing the priorities outlined in the CRCT research agenda will inform clinical trial design for future clinical trials and will enable specific recommendations to be made regarding patient selection and endpoint selection, which will in turn enable robust evidence to be generated that will guide the management of patients with CKD and cardiovascular disease. CKD, chronic kidney disease; CRCT, Cardiovascular and Renal Clinical Trialists; CV, cardiovascular; ESKD, end-stage kidney disease; PRO, patient reported outcome.

Inserm, CHRU, and University of Lorraine, France. The authors acknowledge Colin Baigent and Gene Kelly for their participation in the workshop from which this paper originated. This article reflects the views of the authors and should not be construed to represent FDA's views or policies. This article reflects the views of the authors and do not represent the U.S. National Institutes of Health's views or policies. Peter Mol and Frank Holtkamp are employees of the Dutch Medicines Evaluation Board (MEB), and the views in this paper are not necessarily the views of the MEB.

Conflict of interest: P.R.: Personal fees (consulting) from Novartis, Relypsa, AstraZeneca, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, and CTMA; lecture fees from CVRx; cofounder CardioRenal.

R.A.: Personal fees for Steering Committee membership from Relypsa, Janssen, Bayer, Celgene; personal fees for adjudication committee work from Abbvie, Johnson & Johnson, Janssen, Bayer, Boehringer-Ingelheim; personal fees for Data Safety Monitoring Board participation from Amgen, Celgene, AstraZeneca; personal fees for consulting from Takeda, Daiichi Sankyo, Eli Lilly, Boehringer-Ingelheim, ZS Pharma, Akebia, AstraZeneca, ZS Pharma, Relypsa, OPKO, Celgene, Bayer; research grants from NIH and Veterans Affairs.

B.C.: Full time employee at Fresenius Medical Care Deutschland.

A.C.: Full time employee of Novartis.

G.C.: Nothing to disclose.

J.C.: Nothing to disclose.

W.C.: Research grants from Lilly (institutional grant related to participation as a National Leader and member of Steering Committee in REWIND diabetes cardiovascular outcome trial); uncompensated member of Steering Committee for Takeda-sponsored EXAMINE diabetes cardiovascular outcome trial; uncompensated consulting to Takeda related to hypertension clinical trials.

R.G.: Nothing to disclose.

B.F.: Clinical trial participation (BMS, cardiovascular disease in transplant).

D.G.: Full-time employee of Relypsa, Inc.

N.G.: Full-time employee of AstraZeneca.

F.H.: Nothing to disclose.

G.L.: Nothing to disclose.

Z.M.: Nothing to disclose.

A.M.: Personal fees from speaker honoraria from Abbott, Novartis, Orion, Roche, and Servier; personal fees from advisory board or steering committee participation from Cardiorentis, Adrenomed, MyCartis, ZS Pharma, and Critical Diagnostics.

P.M.: Nothing to disclose.

M.P.: Consultant for AstraZeneca, Bayer, Boehringer Ingelheim, DalCor, Genzyme, Gilead, GlaxoSmithKline, Janssen, Lilly, Medicines Company, Merck, Novartis, Novo Nordisk, Relypsa, Sanofi, Teva, and Thrasos; research grants from Novartis and Sanofi. Other: Stock options DalCor. Patent awarded to BWH regarding the use of inhibitors of the renin-angiotensin system in MI. Licensed by Novartis, Dr. Pfeffer's share irrevocably assigned to charity.

Y.R.: Nothing to disclose.

L.R.: Personal fees for speaking or consulting from AstraZeneca, Bayer (Principal Investigator FIGARO Trial), Novartis, Daiichi-Sankyo, Merck, Menarini, Medtronic, Sanofi.

J.S.: Nothing to disclose.

A.S.: Research grant (to institution) from Novartis; consultancy fees from Myokardia;

S.S.: Nothing to disclose.

B.S.: Employee of ZS Pharma (subsidiary of AstraZeneca); stock options from ZS Pharma; personal fees from Keryx Biopharmaceuticals, Concert Pharmaceuticals, Mallinkrodt Pharmaceuticals, and Fresenius; Board Member Cardio Renal Society of America and Nephronet; issued patent US9375408 B2.

B.S.: Full-time employee of AstraZeneca.

N.S.: Nothing to disclose.

W.G.S.: Consultant to Overcome, European Society of Cardiology, Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America, Relypsa, Stealth Peptides, Celyad, Respicardia, and Coridea.

K.T.: Nothing to disclose.

M.W.: Nothing to disclose.

C.W.: Government research grant for Mirenda study; personal fees from Boehringer-Ingelheim (consultant and steering committee member); pending patent for multiple biomarker approach (EP14163631.6).

D.W.: Nothing to disclose.

C.W.: Nothing to disclose.

J.W.: Statistics Collaborative, her employer, has contracts related to renal disease with Novartis, AstraZeneca, Fibrinogen, Janssen, Relypsa, Reata, Tricida.

B.P.: Personal fees (consulting) from Bayer, KBP Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Merck, Takeda, Relypsa, Tricida; stock options from Relypsa and Tricida; patent pending for site specific delivery of eplerenone to the myocardium.

A.T.: Nothing to disclose.

F.Z.: Personal fees for Steering Committee membership from Janssen, Bayer, Pfizer, Novartis, Boston Scientific, Resmed, Takeda, General Electric, and Boehringer Ingelheim; consultancy for Amgen, CVRx, Quantum Genomics, Relypsa, ZS Pharma, AstraZeneca, GSK; founder of Cardiovascular Clinical Trialists (CVCT).

References

1. Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and mechanisms of uremia-related cardiovascular disease. *Circulation* 2016;**133**:518–536.
2. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015;**373**:2103–2116.
3. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. *Jama* 2006;**296**:1377–1384.
4. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, Coca SG. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. *JAMA Intern Med* 2016;**176**:121–124.
5. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* 2013;**382**:339–352.
6. Ruiz-Hurtado G, Ruilope LM. Does cardiovascular protection translate into renal protection? *Nat Rev Cardiol* 2014;**11**:742–746.
7. Ruiz-Hurtado G, Sarafidis P, Fernandez-Alfonso MS, Waeber B, Ruilope LM. Global cardiovascular protection in chronic kidney disease. *Nat Rev Cardiol* 2016;**13**:603–608.
8. Ishida JH, Johansen KL. Exclusion of patients with kidney disease from cardiovascular trials. *JAMA Intern Med* 2016;**176**:124–125.

9. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. *J Intern Med* 2010;**268**:40–49.
10. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. *Lancet* 2014;**383**:1831–1843.
11. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairitichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de ZD, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* 2011;**377**:2181–2192.
12. Chertow GM, Block GA, Correa-Rotter R, Druke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. *N Engl J Med* 2012;**367**:2482–2494.
13. Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliangryis E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F. Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. *Eur Heart J* 2013;**34**:1621–1629.
14. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Pina IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail* 2013;**15**:1082–1094.
15. Bansal N, Hyre AA, Yang W, Christenson RH, deFilippi CR, Deo R, Dries DL, Go AS, He J, Kusek JW, Lash JP, Raj D, Rosas S, Wolf M, Zhang X, Shlipak MG, Feldman HI. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. *J Am Soc Nephrol* 2015;**26**:946–956.
16. Chawla LS, Herzog CA, Costanzo MR, Tumlin J, Kellum JA, McCullough PA, Ronco C. Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. *J Am Coll Cardiol* 2014;**63**:1246–1252.
17. Lang RM, Badano LP, Mor-Avi V, Afzal J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015;**28**:1–39.
18. Sandoval Y, Herzog CA, Love SA, Cao J, Hu Y, Wu AH, Gilbertson D, Brunelli SM, Young A, Ler R, Apple FS. Prognostic value of serial changes in high-sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients. *Clin Chem* 2016;**62**:631–638.
19. Hicks KA, Tchong JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). *J Am Coll Cardiol* 2015;**66**:403–469.
20. Rossignol P, Pitt B, Thompson A, Zannad F. A roadmap to design future cardiovascular prevention trials in chronic kidney disease. *Lancet* 2016;**388**:1964–1966.
21. Braunschweig F, Kjellstrom B, Soderhall M, Clyne N, Linde C. Dynamic changes in right ventricular pressures during haemodialysis recorded with an implantable haemodynamic monitor. *Nephrol Dial Transplant* 2006;**21**:176–183.
22. Kjellstrom B, Braunschweig F, Lofberg E, Fux T, Grandjean PA, Linde C. Changes in right ventricular pressures between hemodialysis sessions recorded by an implantable hemodynamic monitor. *Am J Cardiol* 2009;**103**:119–123.
23. Stacy SR, Suarez-Cuervo C, Berger Z, Wilson LM, Yeh HC, Bass EB, Michos ED. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: A systematic review. *Ann Intern Med* 2014;**161**:502–512.
24. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. *Eur Heart J* 2012;**33**:2551–2567.
25. Pocock SJ, Clayton TC, Stone GW. Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials. *J Am Coll Cardiol* 2015;**66**:2757–2766.
26. Anker SD, Agewall S, Borggrefe M, Calvert M, Jaime CJ, Cowie MR, Ford I, Paty JA, Riley JP, Swedberg K, Tavazzi L, Wiklund I, Kirchhof P. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. *Eur Heart J* 2014;**35**:2001–2009.
27. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le FC, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. *Eur J Heart Fail* 2016;**18**:482–489.
28. Janssen Research and Development. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CRENCE) (NCT02065791). <https://clinicaltrials.gov/ct2/show/NCT02065791> (1 November 2016).
29. Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. *Int J Epidemiol* 2015;**44**:324–333.
30. Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. *PLoS One* 2012;**7**:e34785.
31. Stafinski T, Menon D, Nardelli A, Bakal J, Ezekowitz J, Tymchak W, Welsh R, Gyenes G, Armstrong PW. Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. *Am Heart J* 2015;**169**:122–131.
32. Canaud B, Hegbrant J, Nissen AR, Barth C, Maddux F, Etter M, Krishnan M. Improving outcomes of dialysis patients by population health management—the Global Chief Medical Officer Initiative. *Lancet* 2016;**388**:1966–1967.